News

Roche’s triple threat—Tecentriq, Cotellic and Zelboraf—stalls melanoma progression

Roche’s triple threat—Tecentriq, Cotellic and Zelboraf—stalls melanoma progression
04/28/2020

Please keep me informed.

Receive comprehensive, breaking news about melanoma, research, legislation, and events.

  • This field is for validation purposes and should be left unchanged.